A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Rasagiline (Azilect)

indicated for the treatment of Parkinson's disease (PD).

First FDA approval2006-07-10
Generic availableYes · 10 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$42.1M in CY2024 Part D spend226K claims · 59K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.01/unit
18 NDCs benchmarked, lowest of all strengths.
Average NADAC
$3.44
Across all dosage forms in distribution.
Highest NADAC
$44.05
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Rasagiline used for?

indicated for the treatment of Parkinson's disease (PD).

Is there a generic for Rasagiline?

Yes. 20 ANDAs filed at FDA, 10 generic manufacturers currently shipping.

How much does my plan pay for Rasagiline?

Across 329 Part D plans, Rasagiline averages $3.44/unit (NADAC). Lowest available: $1.01/unit. Highest in distribution: $44.05/unit.

Is Rasagiline on the FDA shortage list?

No. Rasagiline is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Monoamine Oxidase Inhibitor1 alternative in D1
01
Selegiline
Brand: EMSAM
$0.637Lowest NADAC
4Generic mfrs
$27.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (18 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.